The hypothesis is that the substitution of multi-day oral aprepitant with (intravenous) IV
fosaprepitant, in combination with a 5-HT3 receptor antagonists (5HT3RA) + dexamethasone will
provide comparable protection from 5 day cisplatin chemotherapy induced nausea and vomiting,
compared to the results of our prior study of aprepitant. This study will be the first
clinical trial evaluating fosaprepitant in patients receiving multi-day cisplatin. This will
be a single arm, phase II study. The investigators propose to utilize intravenous (IV)
fosaprepitant on days 3 and 5 of the 5-day cisplatin chemotherapy regimen. It is anticipated
that fosaprepitant can suppress delayed chemo-induced nausea and vomiting for 2-5 days after
therapy. This study will test the value of fosaprepitant in this patient population.
Phase:
Phase 2
Details
Lead Sponsor:
Lawrence Einhorn
Collaborators:
Hoosier Cancer Research Network Merck Sharp & Dohme Corp.